COVID-19 in Patients with Psoriatic Arthritis
##plugins.themes.bootstrap3.article.sidebar##
##plugins.themes.bootstrap3.article.main##
Abstract
The COVID-19 pandemic has a negative impact on all aspects of human life and can lead to the exacerbation of chronic diseases. At the same time, it is known that a higher risk of infection and a more severe course of coronavirus infection is found in the elderly, as well as in people with serious comorbidities.
Psoriatic arthritis (PsA) is a type of inflammatory arthritis that is often diagnosed in patients with psoriasis. Specific treatment of patients with chronic inflammatory joint disease include nonsteroidal anti-inflammatory drugs, glucocorticosteroids, disease-modifying antirheumatic drugs, new biological agents, including monoclonal antibodies to IL-6, IL-1, TNF-a, target disease modifying drugs. Medications used for PsA treatment can potentially have both negative and positive effects on the course of COVID-19.
The objective: to analyze the features of COVID-19 in patients with PsA and to study the comorbid pathology after coronavirus infection.
Materials and methods. The study involved 174 people with a verified diagnosis of PsA. Patients were divided into two groups. Group I included 112 (64.4%) persons who had COVID-19, and group II - 62 (35.6%) who had not had coronavirus infection at the time of first examination.
Patients in group I significantly differed from group II in age (p <0.001) and duration of PsA (p <0.001), showed a significantly higher degree of psoriatic skin lesions and activity of the underlying disease (p = 0.001) compared to patients from group II. The participants of the study underwent examination characterize the course of the psoriatic disease and skin lesions and risk of cardiovascular disease.
Results. To date, there are no clear scientific data that reveal the specific features of COVID-19 infection and the effect of antirheumatic therapy on the development of dangerous complications associated with coronavirus infection in patients with PsA.
The analysis of comorbid pathology has found cardiovascular pathology in 67 (59.8%) of patients, including arterial hypertension – in 58 (51.8%) people, metabolic syndrome – in 34 (30.4%), diseases of the digestive system – in 32 (28.6%) and respiratory system – in 24 (21.4%) of persons.
Conclusions. Patients with higher activity and duration of the PsA were significantly more likely to get COVID-19 and demonstrated higher total cardiovascular risk for the next 10 years.
Further research is needed to study the impact of specific basic rheumatological drugs on the outcomes of COVID-19 and to analyze the broader effects of the pandemic on the course of psoriatic arthritis.
##plugins.themes.bootstrap3.article.details##
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors retain the copyright and grant the journal the first publication of original scientific articles under the Creative Commons Attribution 4.0 International License, which allows others to distribute work with acknowledgment of authorship and first publication in this journal.
References
Singh JA, Guyatt G, Ogdie A, Gladman DD, Deal C, Deodhar A. 2018 American College of Rheumatology/National Psoriasis Foundation Guideline for the Treatment of Psoriatic Arthritis. Arthritis Care Res (Hoboken). 2019;71(1):5–32. doi: 10.1002/art.40726.
D Vanessa O, Gladman D. Psoriatic arthritis. F1000Res. 2019;8:F1000 Faculty Rev-1665. doi: 10.12688/f1000research.19144.1.
Singh JA, Guyatt G, Ogdie A, Gladman DD, Deal C, Deodhar A, et al. Special article: 2018 American College of Rheumatology/National psoriasis Foundation guideline for the treatment of psoriatic arthritis. Arthritis Rheumatol. 2019;71(1):5–32. doi: 10.1002/art.40726.
Mease PJ. Psoriatic Arthritis: update on pathophysiology, assessement and management. Ann Rheum Dis. 2011;70(suppl 1):77–84. doi: 10.1136/ard.2010.140582.
Au K, Reed G, Curtis JR. High disease activity is associated with an increased risk of infection in patients with rheumatoid arthritis. Ann Rheum Dis. 2011;70(5):785–91. doi: 10.1136/ard.2010.128637.
Buckley C, Cavill C, Taylor G, Kay H, Waldron N, Korendowych E, et al. Mortality in psoriatic arthritis – a singlecenter study from the UK. J Rheumatol. 2010;37(10):2141–4. doi: 10.3899/jrheum.100034.
Alinaghi F, Calov M, Kristensen LE, Gladman DD, Coates LC, Jullien D, et al. Prevalence of psoriatic arthritis in patients with psoriasis: A systematic review and meta-analysis of observational and clinical studies. J Am Acad Dermatol. 2019;80(1):251–65. doi: 10.1016/j.jaad.2018.06.027.
Kaine J, Song X, Kim G, Hur P, Palmeret JB, et al. Higher Incidence Rates of Comorbidities in Patients with Psoriatic Arthritis Compared with the General Population Using U.S. Administrative Claims Data. J Manag Care Spec Pharm. 2019;25(1):122–32. doi: 10.18553/jmcp.2018.17421.
Ferguson LD, Siebert S, McInnes IB, Sattar N. Cardiometabolic comorbidities in RA and PsA: lessons learned and future directions. Nat Rev Rheumatol. 2019;15(8):461–74. doi: 10.1038/s41584-019-0256-0.
Fragoulis GE, Bournia V-K, Sfikakis PP. Different systemic rheumatic diseases as risk factors for COVID-19-related mortality. Clin Rheumatol. 2022;41(6):1919–23. doi: 10.1007/s10067-022-06190-3.
Sharma A, Farouk IA, Lal SK. COVID-19: A Review on the Novel Coronavirus Disease Evolution, Transmission, Detection, Control and Prevention. Viruses. 2021;13(2):202. doi: 10.3390/v13020202.
Conway R, Konig MF, Graef ER. Inflammatory arthritis in patients with COVID-19. Transl Res. 2021;232:49–59. doi: 10.1016/j.trsl.2021.02.010.
Alpizar-Rodriguez D. Factors associated with mortality in patients with rheumatic diseases and COVID-19 in Mexico. Ann Rheum Dis. 2021;80:904.
Conway R, Nikiphorou E, Demetriou CA. Temporal Trends in COVID-19 outcomes in People with Rheumatic Diseases in Ireland: data from the COVID-19 Global Rheumatology Alliance registry. Rheumatol (Oxford). 2022;142. doi: 10.1093/rheumatology/keac142.
Al-Adhoubi NK. COVID-19 Mortality in Patients with Rheumatic Diseases: A Real Concern. Curr Rheumatol Rev. 2022;Online ahead of print. doi: 10.2174/1573397118666220412114514.
Piaserico S, Gisondi P, Cazzaniga S, Di Leo S, Naldi L. Assessing the Risk and Outcome of COVID-19 in Patients with Psoriasis or Psoriatic Arthritis on Biologic Treatment: A Critical Appraisal of the Quality of the Published Evidence. J Invest Dermatol. 2022;142(2):355–63. doi: 1016/j.jid.2021.04.036.
Behrangi E, Sadeghzadeh-Bazargan A, Salimi N, Shaka Z, Feyz Kazemi MH, Goodarzi A. Erythrodermic flare-up of psoriasis with COVID-19 infection: A report of two cases and a comprehensive review of literature focusing on the mutual effect of psoriasis and COVID-19 on each other along with the special challenges of the pandemic. Clinical case reports. 2022;10(4):e05722. doi: 10.1002/ccr3.5722.
Kastritis E, Kitas GD, Vassilopoulos D, Giannopoulos G, Dimopoulos MA, Sfikakis PP. Systemic autoimmune diseases, antirheumatic therapies, COVID-19 infection risk and patient outcomes. Rheumatol Int. 2020;40(9):1353–60. doi: 10.1007/s00296-020-04629-x.
Hyrich KL, Machado PM. Rheumatic disease and COVID-19: epidemiology and outcomes. Nat Rev Rheumatol. 2021;17(2):71–2. doi: 10.1038/s41584-020-00562-2.
Smiyan S, Bilukha A. Using q-risk scale for checking cardiovascular risk in patients with psoriatic arthritis. Ann Rheum Dis. 2021;80:1320.
Hippisley-Cox J, Coupland C. Development and validation of QRISK3 risk prediction algorithms to estimate future risk of cardiovascular disease: prospective cohort study. BMJ. 2017;23:357. doi: 10.1136/bmj.j2099.
Garg N, Muduli SK. Comparison of different cardiovascular risk score calculators for cardiovascular risk prediction and guideline recommended statin uses. Indian Heart J. 2017;69(4):458–63. doi: 10.1016/j.ihj.2017.01.015.
Singh JA, Strand V. Spondyloarthritis is associated with poor function and physical health-related quality of life. J Rheumatol. 2009;36(5):1012–20. doi: 10.3899/jrheum.081015.
Ritchlin CT, Colbert RA, Gladman DD. Psoriatic arthritis. N Engl J Med. 2017;376:2095–6.
Gudu T, Gossec L. Quality of life in psoriatic arthritis. Expert Rev Clin Immunol. 2018;14(5):405–17. doi: 10.1080/1744666X.2018.1468252.
